 The study involves a double-blind placebo-controlled parallel group design. Participants n132 will be randomized to receive either oral creatine supplementation or placebo 21 gd for 7 days. One leg of each participant will be randomized to receive topical creatine 3.5 mLd and the opposite leg placebo for 7 days. 